FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019089968> ?p ?o ?g. }

• W2019089968 endingPage "18" @default.
• W2019089968 startingPage "18" @default.
• W2019089968 abstract "Type 2 diabetes (T2D) is strongly associated with cardiovascular risk and requires medications that improve glycemic control and other cardiovascular risk factors. The authors aimed to assess the relative effectiveness of pioglitazone (Pio), metformin (Met) and any sulfonylurea (SU) combinations in non-insulin-treated T2D patients who were failing previous hypoglycemic therapy.Over a 1-year period, two multicenter, open-labeled, controlled, 1-year, prospective, observational studies evaluated patients with T2D (n = 4585) from routine clinical practice in Spain and Greece with the same protocol. Patients were eligible if they had been prescribed Pio + SU, Pio + Met or SU + Met serving as a control cohort, once they had failed with previous therapy. Anthropometric measurements, lipid and glycemic profiles, blood pressure, and the proportions of patients at microvascular and macrovascular risk were assessed.All study treatment combinations rendered progressive 6-month and 12-month lipid, glycemic, and blood pressure improvements. Pio combinations, especially Pio + Met, were associated with increases in HDL-cholesterol and decreases in triglycerides and in the atherogenic index of plasma. The proportion of patients at high risk decreased after 12 months in all study cohorts. Minor weight changes (gain or loss) and no treatment-related fractures occurred during the study. The safety profile was good and proved similar among treatments, except for more hypoglycemic episodes in patients receiving SU and for the occurrence of edema in patients using Pio combinations. Serious cardiovascular events were rarely reported.In patients with T2D failing prior hypoglycemic therapies, Pio combinations with SU or Met (especially Pio + Met) improved blood lipid and glycemic profiles, decreasing the proportion of patients with a high microvascular or macrovascular risk. The combination of Pio with SU or Met may therefore be recommended for T2D second-line therapy in the routine clinical practice, particularly in patients with dyslipidemia." @default.
• W2019089968 created "2016-06-24" @default.
• W2019089968 creator A5016017037 @default.
• W2019089968 creator A5016467806 @default.
• W2019089968 creator A5021614010 @default.
• W2019089968 creator A5044502073 @default.
• W2019089968 creator A5058676633 @default.
• W2019089968 creator A5085205644 @default.
• W2019089968 date "2011-01-01" @default.
• W2019089968 modified "2023-09-26" @default.
• W2019089968 title "Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study" @default.
• W2019089968 cites W1963542379 @default.
• W2019089968 cites W1969533014 @default.
• W2019089968 cites W1971172093 @default.
• W2019089968 cites W1977235023 @default.
• W2019089968 cites W1979369530 @default.
• W2019089968 cites W1980463553 @default.
• W2019089968 cites W1986373594 @default.
• W2019089968 cites W1990724339 @default.
• W2019089968 cites W1997416444 @default.
• W2019089968 cites W1999892605 @default.
• W2019089968 cites W2023239847 @default.
• W2019089968 cites W2023447984 @default.
• W2019089968 cites W2028038659 @default.
• W2019089968 cites W2028596300 @default.
• W2019089968 cites W2030921297 @default.
• W2019089968 cites W2035576567 @default.
• W2019089968 cites W2037946574 @default.
• W2019089968 cites W2043269192 @default.
• W2019089968 cites W2050758709 @default.
• W2019089968 cites W2052856694 @default.
• W2019089968 cites W2053365438 @default.
• W2019089968 cites W2072664557 @default.
• W2019089968 cites W2073826830 @default.
• W2019089968 cites W2074047111 @default.
• W2019089968 cites W2077008924 @default.
• W2019089968 cites W2079283767 @default.
• W2019089968 cites W2086393043 @default.
• W2019089968 cites W2096119329 @default.
• W2019089968 cites W2097870088 @default.
• W2019089968 cites W2098108405 @default.
• W2019089968 cites W2102108180 @default.
• W2019089968 cites W2105407506 @default.
• W2019089968 cites W2106343349 @default.
• W2019089968 cites W2107166617 @default.
• W2019089968 cites W2108606693 @default.
• W2019089968 cites W2113309725 @default.
• W2019089968 cites W2114783994 @default.
• W2019089968 cites W2117205405 @default.
• W2019089968 cites W2124533387 @default.
• W2019089968 cites W2127125241 @default.
• W2019089968 cites W2129514415 @default.
• W2019089968 cites W2131490500 @default.
• W2019089968 cites W2133377772 @default.
• W2019089968 cites W2139562487 @default.
• W2019089968 cites W2142271188 @default.
• W2019089968 cites W2150556712 @default.
• W2019089968 cites W2154067841 @default.
• W2019089968 cites W2158260242 @default.
• W2019089968 cites W2159969745 @default.
• W2019089968 cites W2163498104 @default.
• W2019089968 cites W2171294019 @default.
• W2019089968 cites W2172488527 @default.
• W2019089968 cites W2282948130 @default.
• W2019089968 cites W2527670279 @default.
• W2019089968 cites W3109617681 @default.
• W2019089968 doi "https://doi.org/10.1186/1475-2840-10-18" @default.
• W2019089968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3042924" @default.
• W2019089968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21314919" @default.
• W2019089968 hasPublicationYear "2011" @default.
• W2019089968 type Work @default.
• W2019089968 sameAs 2019089968 @default.
• W2019089968 citedByCount "9" @default.
• W2019089968 countsByYear W20190899682012 @default.
• W2019089968 countsByYear W20190899682013 @default.
• W2019089968 countsByYear W20190899682015 @default.
• W2019089968 countsByYear W20190899682017 @default.
• W2019089968 countsByYear W20190899682019 @default.
• W2019089968 countsByYear W20190899682020 @default.
• W2019089968 crossrefType "journal-article" @default.
• W2019089968 hasAuthorship W2019089968A5016017037 @default.
• W2019089968 hasAuthorship W2019089968A5016467806 @default.
• W2019089968 hasAuthorship W2019089968A5021614010 @default.
• W2019089968 hasAuthorship W2019089968A5044502073 @default.
• W2019089968 hasAuthorship W2019089968A5058676633 @default.
• W2019089968 hasAuthorship W2019089968A5085205644 @default.
• W2019089968 hasBestOaLocation W20190899681 @default.
• W2019089968 hasConcept C126322002 @default.
• W2019089968 hasConcept C134018914 @default.
• W2019089968 hasConcept C201903717 @default.
• W2019089968 hasConcept C23131810 @default.
• W2019089968 hasConcept C2777180221 @default.
• W2019089968 hasConcept C2778384471 @default.
• W2019089968 hasConcept C2778854520 @default.
• W2019089968 hasConcept C2779306644 @default.
• W2019089968 hasConcept C2780323712 @default.
• W2019089968 hasConcept C2780473172 @default.
• W2019089968 hasConcept C555293320 @default.

• next